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Abstract
Background: TRAIL plays an important role in host immunosurveillance against tumor progression, as it
induces apoptosis of tumor cells but not normal cells, and thus has great therapeutic potential for cancer
treatment. TRAIL binds to two cell-death-inducing (DR4 and DR5) and two decoy (DcR1, and DcR2)
receptors. Here, we compare the expression levels of TRAIL and its receptors in normal oral mucosa
(NOM), oral premalignancies (OPM), and primary and metastatic oral squamous cell carcinomas (OSCC)
in order to characterize the changes in their expression patterns during OSCC initiation and progression.
Methods: DNA microarray, immunoblotting and immunohistochemical analyses were used to examine
the expression levels of TRAIL and its receptors in oral epithelial cell lines and in archival tissues of NOM,
OPM, primary and metastatic OSCC. Apoptotic rates of tumor cells and tumor-infiltrating lymphocytes
(TIL) in OSCC specimens were determined by cleaved caspase 3 immunohistochemistry.
Results: Normal oral epithelia constitutively expressed TRAIL, but expression was progressively lost in
OPM and OSCC. Reduction in DcR2 expression levels was noted frequently in OPM and OSCC compared
to respective patient-matched uninvolved oral mucosa. OSCC frequently expressed DR4, DR5 and DcR1
but less frequently DcR2. Expression levels of DR4, DR5 and DcR1 receptors were not significantly altered
in OPM, primary OSCC and metastatic OSCC compared to patient-matched normal oral mucosa.
Expression of proapoptotic TRAIL-receptors DR4 and DR5 in OSCC seemed to depend, at least in part,
on whether or not these receptors were expressed in their parental oral epithelia. High DR5 expression
in primary OSCC correlated significantly with larger tumor size. There was no significant association
between TRAIL-R expression and OSSC histology grade, nodal status or apoptosis rates of tumor cells
and TIL.
Conclusion: Loss of TRAIL expression is an early event during oral carcinogenesis and may be involved
in dysregulation of apoptosis and contribute to the molecular carcinogenesis of OSCC. Differential
expressions of TRAIL receptors in OSCC do not appear to play a crucial role in their apoptotic rate or
metastatic progression.
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TRAIL (tumor necrosis factor-related apoptosis-inducing
ligand; Apo2L) is a type II transmembrane protein which
selectively induces apoptosis in tumor cells but not nor-
mal cells [1,2]. Because of this differential sensitivity
TRAIL is considered an ideal anticancer drug [3,4]. It inter-
acts with four distinct surface receptors, TRAIL-R1 (DR4),
-R2 (DR5), -R3 (DcR1), and R4 (DcR2) and with the sol-
uble receptor osteoprotegerin [1,2]. DR4 and DR5 act as
transmembrane signaling death receptors with cytoplas-
mic death domains (DD) which respond to ligand bind-
ing and activate the extrinsic cell death pathway by
facilitating interaction between the specific adapter pro-
tein (FAS-associated DD) and proapoptotic effector pro-
teins (caspases 8 and 10) [5]. DcR1 and DcR2 (decoy
receptors), conversely, cannot mediate apoptosis because
they lack functional DD [6]. It has been suggested that the
differences in the expression levels of death (DR4 and
DR5) versus decoy (DcR1 and DcR2) receptors can deter-
mine the sensitivity of tumor cells to TRAIL-induced
apoptosis [6]. However, susceptibility to TRAIL-induced
apoptosis does not always correlate well with the cell sur-
face expression levels of death-inducing and decoy TRAIL
receptors suggesting a regulatory role for downstream sig-
naling and effector molecules [7,8]. Furthermore, recent
studies indicate that TRAIL susceptibility of tumors in vivo
is modified by tumor microenvironmental factors and
tumor hypoxia [9,10].
Recombinant TRAIL protein (rTRAIL) induces significant
tumor regression in mice bearing human tumor
xenografts without producing any serious systemic effects
in the host [11,12]. Importantly, radiation and certain
chemotherapeutic drugs increase the susceptibility of
tumor cells to rTRAIL and agonistic TRAIL-R antibodies
[13-17]. Hence, combinations of rTRAIL + chemotherapy
or TRAIL + radiation produce synergistic anti-tumor
effects both in vitro and in mice bearing human tumor
xenografts [18]. Human rTRAIL (PRO1762) and mono-
clonal antibodies that induce trimerization of DR4 (HGS-
ETR 1) and DR5 (HGS-ETR 2) are currently undergoing
phase Ib and II clinical evaluations, respectively [19].
Moreover, use of DR4 (HGS-ETR1) agonist antibody as a
single agent or in combination with chemotherapy has
been shown to stabilize disease in patients with advanced
head and neck cancer [20]. In addition to its therapeutic
potential, endogenously expressed TRAIL is an effector
molecule important for the host's antitumor immune
response [2,21,22].
Despite various treatment approaches, most patients with
advanced oral squamous cell carcinomas (OSCC) develop
local or regional recurrences (50–60%) and metastatic
disease (~20%) leading to poor survival rate. Therefore,
there is an unmet need for more efficacious and less toxic
molecularly targeted therapies for treating OSCC. Recent
preclinical and clinical data have shown the potential util-
ity of TRAIL-R targeted therapies in advanced cancers,
including OSCC [4,19,23]. Currently, there are only lim-
ited data available pertaining to the baseline expression
levels of TRAIL and its receptors in normal oral mucosa,
oral premalignancies (OPM) and primary or metastatic
oral squamous cell carcinoma (OSCC) [24,25]. These data
are critical to analysis and interpretation of clinical trial
data involving rTRAIL and TRAIL receptor agonist anti-
bodies in OSCC patients, as well as the understanding of
the role of TRAIL and its receptors during oral carcinogen-
esis. In the present study we determined changes in the
expression of TRAIL and TRAIL-R during OSCC develop-
ment and progression by comparing expression patterns
in normal oral mucosa (NOM), oral premalignancies
(OPM), primary OSCC and metastatic OSCC. We also
correlated the expression levels of TRAIL-receptor in
OSCC with various clinicopathologic prognosticators.
Finally we correlated the apoptosis rate of tumor cells and
tumor-infiltrating lymphocytes (TIL) in OSCC with their
respective TRAIL and TRAIL-R expression patterns.
Methods
Cell lines and human tissue
Normal human oral mucosal epithelia cells (NOM) were
established from discarded human gingival tissue. NOM
cells within their first two serial passages in culture were
used for RNA isolation and cellular protein extraction.
Details related to OPM (Leuk1 & Leuk2), primary OSCC
(686Tu, 1386Tu and 101A) and metastatic OSCC (686Ln
and 1386Ln) cell lines have been described previously
[7,26-28]. HOK-16B is a normal oral keratinocyte-derived
cell line immortalized by transfection with HPV-16
genome [29]. Chronic exposure of HOK-16B cells with
benzo (a) pyrene produced the tumorigenic HOK-16B-
Bap-T cell line [29]. NOM, Leuk1, Leuk2 and HOK-16B
cells were grown in keratinocyte growth media (KGM-2)
supplemented with growth factor Bullit kit (Cambrex,
East Rutherford, NJ, USA). HOK-16B-BaP-T and OSCC
cell lines were maintained in DMEM/F12 50/50 mix
(Cambrex) containing 10% fetal bovine serum, 0.4 μg/ml
hydrocortisone, and penicillin-streptomycin-amphoter-
icin antibiotic mix.
Archival tissue specimens from primary OSCC (n = 45)
and corresponding lymph node metastases (n = 11) were
used for light microscopic and immunohistochemical
studies (Table 1). Oral leukoplakias with moderate to
severe dysplasia (n = 25) were used as OPM specimens.
Five μm serial sections were cut from each specimen and
processed for H&E and immunohistochemical staining.
The histological grading of OPM and OSCC was deter-
mined by two pathologists using H&E stained sections
according to published criteria [30]. All tissue specimensPage 2 of 13
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the guidelines and approval of the Institutional Review
Boards of The University of Texas Health Science Center at
Houston.
Microarray data sets
We interrogated the expression levels of TRAIL and its
receptors in our pre-existing microarray data sets on the
above oral cell lines representing different phenotypes.
Relative RNA expression levels were determined using
Affymetrix U133A oligonucleotide microarrays (33,000
annotated genes) as described [27,28]. Either two or four
biological replicate experiments were done independently
by two different investigators. The U133A array included
three different probe sets for TRAIL (NM_003810), DR5
(TRAIL-R2; NM_003842) and DcR1 (TRAIL-R3;
NM_003841) and one probe set for DcR2 (TRAIL-R4;
NM_003840), but no probe sets for TRAIL receptor DR4
(TRAIL-R1; NM_003844). Signal intensity for each gene
was calculated using the Affymetrix MAS 5.0 probe level
algorithm. Phenotypic-specific gene expression values for
TRAIL, DR5, DcR1 and DcR2 genes were calculated by
averaging signal intensities across sample replicates for
cell lines belonging to each phenotypic group.
Western blotting for TRAIL protein
TRAIL protein levels were examined by Western blotting
in cell extracts of NOM cells from two different patients
(NOM-1 & 2), OPM cell line Leuk1, and from primary
(1386Tu) and metastatic (1386Ln) OSCC cell lines. These
cellular extracts were separated by 12% SDS-PAGE and
transferred to nitrocellulose membrane (Novex, San
Diego, CA). The membranes were incubated in blocking
solution (5% milk powder in 10 mM TRIS-HCl, pH 8.0,
150 mM NaCl, 0.1% Tween 20) at room temperature for
1 h, then immunoblotted with polyclonal goat anti-
human TRAIL (1: 200, Santa Cruz Biotechnology, CA,
USA) or monoclonal mouse anti-βactin (Sigma-Aldrich
Co, St. Louis, MO) antibody followed by horseradish per-
oxidase-conjugated secondary antibody and chemilumi-
nescence detection.
Immunohistochemistry
We investigated TRAIL and its receptor expression by sem-
iquantitative immunohistochemistry in 25 OPMs (leuko-
plakias with moderate to severe dysplasia) and in 45
primary OSCCs and 9 patient-matched metastatic OSCCs.
Tissue sections were deparaffinized, rehydrated, and sub-
jected to antigen retrieval by heating in target antigen
retrieval solution (DakoCytomation, Carpinteria, CA,
USA) according to the manufacturer's protocol. Polyclo-
nal antibodies against human TRAIL (goat anti-TRAIL,
Santa Cruz, CA. USA; 1:40), DR4 (goat anti-DR4, Santa
Cruz, CA., USA; 1:50), DR5 (rabbit anti-DR5, Oncogene,
CA., USA; 1:100), DcR1 (rabbit anti-DcR1, Oncogene, CA,
USA; 1:50) and DcR2 (rabbit anti-DcR1, Oncogene, CA,
USA; 1:25) were used for immunohistochemical detec-
tion. Apoptotic rates of OSCC cells and tumor-infiltrating
lymphocytes (TIL) were determined by immunohisto-
chemical detection of cleaved caspase 3 (Rabbit anti-
cleaved caspase 3, Cell Signaling, CA, USA, 1:50) [31].
Immunoreactive sites were visualized using the standard
Streptavidin-Biotin-HRP detection method, using diami-
nobenzidine tetrachloride as chromogenic substrate.
Pathological and immunohistochemical evaluations
Immunoreactive patterns of TRAIL and its receptors were
compared with uninvolved mucosa adjacent to the epi-
thelial dysplasias and invasive tumors. Expression levels
of TRAIL and its receptors were evaluated semiquantita-
tively by two independent examiners as described [32]. A
score from 0 (no staining) to 4 (strong immunoreactivity)
was assigned to staining intensity, and the percentage of
positive cells for each staining intensity in tumors and
dysplastic areas of leukoplakias was determined. Immu-
noreactive scores (range 0 – 4) were calculated by multi-
plying percentage of positive cells times staining intensity
score. Cleaved caspase-3 positive tumor cells and TIL in
randomly selected five to seven high-power (200 ×) fields
(HPF) across the tumor section were counted using Image
Pro Plus V (Media Cybernetics, Silver Spring, MD, USA).
Caspase 3 labeling index (LICasp) for each tumor is
expressed as average # positive cells/HPF.
Statistical analysis
Two-sample t-test and one-way ANOVA were used to
determine the statistical significance of the differences in
TRAIL and its receptors expression levels in OPM and
OSCC with various clinicopathologic parameters. Pear-
son's correlation was used to test the relationship between
TRAIL-R expression patterns of uninvolved oral mucosa,
and primary and metastatic tumor from the same patient.
Table 1: Clinical data of the OSCC specimens used in this study
Parameter No of cases (%)
Median age: 42 Y 42 (100)
Age range (years): 37–81 Y
Sex
Male 29 (69)
Female 13 (31)
Site
Buccal mucosa 2 (5)
Tonsillar area 7 (17)
Retromolar pad 3 (7)
Gingiva 2 (5)
Floor of the mouth 8 (19)
Tongue 15 (36)
Unknown 5 (11)Page 3 of 13
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TRAIL, DR5, DcR1 and DcR2 RNA expression levels in 
normal, premalignant and malignant oral epithelial cells in 
vitro
TRAIL mRNA was detectable in all samples; however its
expression level was significantly (p ≤ 0.001) higher in
NOM cells (mean ± SD = 364.9 ± 20.4) compared to
immortalized oral epithelia (HOK-16B; mean ± SD = 23.3
± 10.6), OPM (Leuk1 and Leuk 2 cells mean ± SD = 48.2
± 20.1), malignant primary (686Tu, 1386Tu, HOK-16B-
Bap-Tu &101A; mean ± SD = 25.3 ± 11.3) and metastatic
(686Ln and 1386Ln; mean ± SD = 32.5 ± 4.8) oral epithe-
lial cells (Figure 1). Among the TRAIL receptors, DR5
mRNA was consistently higher (> 5-fold) in all cell lines
compared to low mRNA levels of DcR1 and DcR2 (Figure
2). DR4 expression levels were not available in our micro-
array database. There were no significant differences in the
expression levels of all three TRAIL receptors among nor-
mal, immortalized, premalignant, and malignant primary
and metastatic oral epithelial cells (Figure 2). Western
blotting analysis showed that TRAIL protein is detectable
as a 24 kD band only in NOM cells but not in OPM and
OSCC cells (Figure 3). We previously reported that expres-
sion of DR4, DR5, DcR1 and DcR2 proteins in primary
and metastatic OSCC cells were not significantly different
[7].
Expression levels of TRAIL-R, DR5, DcR1 and DcR2 are not significantly different among normal (NOM), immortalized (16B), premalignant (OPM), and alignant pr ary (Iry) a d metast tic (Met) oral epithelial cellsFigure 2
Expression levels of TRAIL-R, DR5, DcR1 and DcR2 are not 
significantly different among normal (NOM), immortalized 
(16B), premalignant (OPM), and malignant primary (Iry) and 
metastatic (Met) oral epithelial cells. Relative RNA expres-
sion levels of TRAIL-R were determined using Affymetrix 
U133A oligonucleotide microarrays and their signal intensi-
ties were calculated using the Affymetrix MAS 5.0 probe 
level algorithm. Phenotypic-specific gene expression values 
for DR5, DcR1 and DcR2 genes were calculated by averaging 
signal intensities across sample replicates for cell lines 
belonging to each phenotypic group. The mRNA levels of 
DR5 are significantly higher than the DcR1 and DcR2 mRNA 
levels in these cell lines. The DNA microarray chips used in 
this study did not have the probe sets for DR4. NOM: Nor-
mal oral epithelial cells; 16B: Immortalized normal oral epi-
thelial cells; OPM: Average target intensities of premalignant 
cell lines MSK-Leuk1 and MSK-Leuk2; 16BTu: tumorigenic 
cell line derived from HOK-16B; Iry: Average target intensi-
ties of primary OSCC cell lines 1386TU, 686Tu and 101A. 
Met: Average target intensities of metastatic OSCC cell lines 
1386Ln and 686Ln.
TRAIL mRNA levels are markedly higher in normal oral epi-thelial cells (NOM) in co parison to immortalized (16B), pr malignant (L1 and L2) and malignant oral epithe ial cells (16BTu, 1386Tu, 686Tu, 101A, 1386Ln and 686Ln)Figure 1
TRAIL mRNA levels are markedly higher in normal oral epi-
thelial cells (NOM) in comparison to immortalized (16B), 
premalignant (L1 and L2) and malignant oral epithelial cells 
(16BTu, 1386Tu, 686Tu, 101A, 1386Ln and 686Ln). Relative 
RNA expression levels of TRAIL were determined using 
Affymetrix U133A oligonucleotide microarrays. Signal inten-
sity for TRAIL was calculated using the Affymetrix MAS 5.0 
probe level algorithm. NOM: Normal oral epithelial cells; 
16B: Normal oral epithelial cells immortalized by HPV-16 
transfection (HOK-16B). L1: OPM cell line MSK-Leuk1; L2: 
OPM cell line MSK-Leuk2; 16BTu: tumorigenic cell line 
derived from HOK-16B; (HOK-16B-Bap-T); 1386Tu, 
686Tu and 101A: Cell lines derived from primary OSCC. 
1386Ln and 686Ln: Cell lines derived from synchronous 
lymph node metastases of 1386Tu and 686Tu tumors.
TRAIL protein is detectable only in normal oral epithelial cells (lanes 1 and 2) but not in premalig ant (lane 3) and ma gnant oral epithelial cell lines (lanes 4 and 5)Figure 3
TRAIL protein is detectable only in normal oral epithelial cells (lanes 1 
and 2) but not in premalignant (lane 3) and malignant oral epithelial 
cell lines (lanes 4 and 5). Total cellular proteins were extracted from 
two normal oral epithelial samples (NOM-1 and 2-lanes 1 and 2), 
OPM cell line (MSK-Leuk1-lane 3), primary OSCC cell line (1386Tu-
lane 4) and metastatic OSCC cell line (1386Ln-lane 5) and analyzed 
for TRAIL protein by Western blotting. NS: none specific bands.Page 4 of 13
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All OPM specimens (leukoplakias/erythroplakias with
moderate to severe dysplasia) used in this study had nor-
mal oral mucosa (NOM) adjacent to the dysplasia. Of the
25 cases of oral leukoplakias with dysplasia, 56% and
44% of them had moderate and severe dysplasia, respec-
tively. Stratified squamous epithelium of the NOM exhib-
ited membrane and cytoplasmic immunoreactivity for
DR4, DR5, DcR1 and DcR2 (Figures 4, 5, 6, 7, 8, 9, 10).
Cytoplasmic TRAIL protein was constitutively expressed
by NOM (Figures 4, 5). Moreover, DR4, DR5 and DcR1
were expressed in all dysplastic oral epithelia (Figures 4,6,
7). On the other hand, TRAIL expression was lost in dys-
plasia compared to adjacent NOM (Figures 4, 5, 8). Stain-
ing intensity for DcR2 was also lower in dysplasia than in
adjacent NOM (Figures 4 &7).
Expression of TRAIL and TRAIL-R in primary and 
metastatic OSCC specimens
Forty-two primary OSCC and nine patient-matched cervi-
cal lymph node metastases, including NOM adjacent to
the primary OSCC, were examined for TRAIL and TRAIL-
R expression patterns (Table 1). Expression levels of each
TRAIL-R in uninvolved oral mucosa adjacent to primary
OSCC were determined and their Pearson correlation
coefficient was calculated to be 0.898 for DR4, 0.863 for
DR5 and 0.754 for DcR1 with a two-tailed P value of <
0.001, indicating a strong correlation in their expression
patterns between primary tumors and matched unin-
volved oral mucosae. A similar correlation was not
observed for DcR2. TRAIL protein was completely nega-
tive in 27% of the OSCC cases examined; the remaining
OSCC revealed only a few (< 5%) isolated tumor cells
with cytoplasmic staining for TRAIL (Data not shown).
TRAIL-R in primary OSCC demonstrated marked inter-
and intratumoral heterogeneity in their staining patterns.
DR4 was expressed in 98% of OSCC (41/42 cases) (IHC
score: mean ± SD = 2.24 ± 0.918; range 0.5 – 4) and 57%
DR4 and DR5 immunohistochemical staining of the lesion shown in figure 5 (× 100)Figure 6
DR4 and DR5 immunohistochemical staining of the lesion 
shown in figure 5 (× 100). Immunoreactivity for either DR4 
(top) or DR5 (bottom) is not altered in dysplasia compared 
to adjacent uninvolved mucosa.
The expression levels of TRAIL and DcR2 are markedly reduced in oral premalignancy compared to normal oral mucosaFig r  4
The expression levels of TRAIL and DcR2 are markedly 
reduced in oral premalignancy compared to normal oral 
mucosa. Graphic depiction of the mean expression levels of 
TRAIL and TRAIL-R in patient matched normal oral mucosa 
(NOM), oral premalignancies (OPM: leukoplakias with dys-
plasia). Mean expression levels of DR4, DR5 and DcR1 did 
not differ significantly between normal oral mucosa (NOM) 
and oral premalignancies (OPM).
Loss of TRAIL expression in oral leukoplakia with moderate epithelial dysplasiaFigure 5
Loss of TRAIL expression in oral leukoplakia with moderate 
epithelial dysplasia. A: Hematoxylin and eosin staining; B: 
Immunohistochemical staining for TRAIL (× 100). Note that 
immunoreactivity for TRAIL is significantly reduced in dyspla-
sia (arrows) compared to adjacent uninvolved mucosa (N).Page 5 of 13
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(IHC score ≥ 2) (Figure 11). Thirty-nine of 42 OSCC cases
(93%) were positive for DR5 (IHC score: mean ± SD =
1.362 ± 0.696; range 0.5 – 3.2) and 21% of these tumors
were high expressors (IHC score ≥ 2) for DR5 (Figure 11).
All OSCC were positive for either DR4 or DR5 and none
of them were negative for both receptors. Among the
TRAIL decoy receptors, DcR1 was expressed in all OSCC
cases (IHC score: mean ± SD = 2.52 ± 0.674; range 1.0 –
4) and 71% of these cases expressed high levels (IHC score
≥ 2) of DcR1 (Figure 11). On the other hand, DcR2 was
positive in 62% (26/42) of OSCC cases (IHC score: mean
± SD = 0.628 ± 0.483; range 0.5 – 2.3) but was expressed
in high levels only in one case (Figure 11). Expression lev-
els of DR4, DR5, DcR1 and DcR2 in metastatic OSCC were
not significantly different from their patient-matched pri-
mary tumors (Figure 11).
TRAIL-R expression levels and clinicopathologic 
parameters
We examined the relationship between TRAIL-R expres-
sion and various prognostic factors. There was no signifi-
DR4 and DR5 immunohistochemical staining of the lesion shown in figure 8 (× 100)Figure 9
DR4 and DR5 immunohistochemical staining of the lesion 
shown in figure 8 (× 100). Dysplastic epithelium and associ-
ated mononuclear immune cell infiltrate (MNC) demonstrate 
intense staining for both DR4 and DR5.
DcR1 and DcR2 immunohistochemical staining of the lesion shown i  figure 5 (× 100)Figure 7
DcR1 and DcR2 immunohistochemical staining of the lesion 
shown in figure 5 (× 100). Immunoreactivity for DcR1 (top) 
is not altered in dysplasia compared to adjacent uninvolved 
mucosa. Focal loss of DcR2 expression (bottom) is noted in 
dysplasia compared to adjacent uninvolved mucosa.
Loss of TRAIL expression pattern in oral leukoplakia with severe dysplasiaFigure 8
Loss of TRAIL expression pattern in oral leukoplakia with 
severe dysplasia. A: Hematoxylin and eosin staining (× 100); 
B: Immunohistochemical staining for TRAIL (× 100). Note 
that TRAIL expression is mostly lost in dysplastic epithelium 
(arrow). In contrast, mononuclear immune cell infiltrate 
(MNC) associated with dysplasia reveals intense staining for 
TRAIL.Page 6 of 13
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expression with either tumor size (T) or nodal status (N)
or histologic grade of the primary tumor (Table 2). Expres-
sion levels of DR5 in primary OSCC correlated positively
with tumor size (p = 0.03) but failed to show any signifi-
cant correlation with either nodal status or histologic
tumor grade (Table 3).
TRAIL-R expression levels and apoptosis rates in tumor 
cells and tumor infiltrating lymphocytes (TIL)
We determined the apoptosis rates of tumor cells and TIL
by measuring their cleaved caspase 3 labeling indices
(LICasp) in primary OSCC (Figure 12). The overall LICasp of
tumor cells was 3.4/HPF (LICasp-TU = 3.4 ± 2.6; range = 0.2
– 12.2), and LICasp of TIL was 6.9/HPF (LICasp-TIL = 6.9 ±
5.2; range = 0.6–25). There were no significant associa-
tions between the tumor cells or TIL apoptosis rates and
tumor size (T) or nodal status (N) (Table 3). However,
basaloid squamous cell carcinoma, which is a highly
aggressive variant of OSCC, exhibited significantly higher
LICasp-TIL compared to the conventional OSCC (Table 3).
We also examined the correlation between TRAIL and
TRAIL-R expression levels and apoptosis rate among
tumor cells and tumor infiltrating lymphocytes (Table 3).
There was no significant relationship between the expres-
sion levels of all four TRAIL-R in tumor cells and their
apoptosis rate (Table 3). Moreover apoptosis rates of TIL
in OSCC did not differ significantly between TRAIL- posi-
tive and -negative tumors (Table 3).
Discussion
We and others have demonstrated that OSCC cells are sus-
ceptible to TRAIL-induced apoptosis [7,10,33]. A Phase 1
clinical study of TRAIL-R agonist antibody (HGS-ETR1) in
patients with advanced solid malignancies including head
and neck cancer has proven its safety and biological activ-
ity as measured by durable stable disease in these patients
[20]. Our study, however, is the first to characterize and
compare alterations in TRAIL and TRAIL-R in normal oral
epithelia, OPM and OSCC. Our data document the fol-
lowing important findings: 1. Normal oral epithelia con-
stitutively expressed TRAIL, but its expression was
progressively lost in OPM and OSCC. 2. Reduction in
DcR2 expression level was noted frequently in OPM and
OSCC compared to respective patient-matched unin-
volved oral mucosa. 3. Expression levels of DR4, DR5 and
DcR1 receptors were not significantly altered in OPM, pri-
mary OSCC or metastatic OSCC compared to patient-
matched normal oral mucosa. 4. Expression of proapop-
totic TRAIL-receptors DR4 and DR5 in OSCC seemed to
depend, at least in part, on whether or not these receptors
were expressed in their parental oral epithelia. 5. High
DR5 expression in primary OSCC correlated significantly
with larger tumor size. 6. There was no significant associ-
ation between TRAIL-R expression and OSSC histology
grade, nodal status, or apoptosis rates of tumor cells and
TIL.Loss of TRAIL expression is an early event during oral
carcinogenesis
The functional role of TRAIL, which is constitutively
expressed in most normal tissues, is poorly understood.
Recently, however, TRAIL has been shown to trigger apop-
tosis in transformed or dysplastic epithelial cells, suggest-
ing a therapeutic potential as a chemopreventive agent
against malignant progression of premalignancies
[19,34,35]. OPM is considered a progenitor of OSCC and
represents an intermediate step in the progression from
NOM to OSCC [30]. The likelihood for development of
OSCC in OPM is generally proportional to its dysplasia
grade [30]. Our data revealed that TRAIL, which is
expressed in normal oral epithelia, was progressively lost
in OPM with increasing dysplasia grade. This was further
supported by our microarray data in which TRAIL mRNA
levels were 8-fold higher in NOM cells compared to OPM
cells. Finally, our immunoblotting data confirmed that
TRAIL protein was detectable only in NOM cells not in
OPM cells. Similar loss of TRAIL expression during the
DcR1 and DcR2 immunohistochemical staining of the lesion shown i  figure 8 (× 100)Figure 10
DcR1 and DcR2 immunohistochemical staining of the lesion 
shown in figure 8 (× 100). Dysplastic epithelium and associ-
ated mononuclear immune cell infiltrate (MNC) are positive 
for both DcR1 and DcR2.Page 7 of 13
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been reported in skin, esophageal and colon cancers [36-
38].
The loss of individual TRAIL-R expression in malignant
tumors has been attributed to chromosomal gene muta-
tion/deletion (DR4 and DR5) or promotor methylation
(DcR1 and DcR2) events [4]. However, gene mutation or
promotor methylation is not implicated for the malig-
nancy-specific down-regulation of TRAIL expression.
Recent experimental findings indicate that loss of TRAIL
expression during malignant transformation is not medi-
ated by genetic aberration but by dysregulation of signal
transduction pathways common to various cancers. TNF-
α increases the susceptibility of breast cancer cells to
chemotherapy by up-regulating TRAIL expression by pro-
moter activation [39]. Similarly, retinoids and interferons
exert their anticancer activity in breast cancer cells by
enhancing TRAIL expression in these cells [40]. Hyperac-
tivation of the phosphatidylinositol 3-kinase (PI-3K)/Akt
pathway has been implicated in suppressing TRAIL
expression in colon cancer cells [41]. Treatment of colon
cancer cells with the PI-3K inhibitor Wortmannin rescues
TRAIL expression in these cells and induces enterocyte-
like differentiation  [41]. Interestingly, hyperactivation of
PI-3K/AKT pathway via dysregulated EGFR signaling is an
important and early event in the pathogenesis of OSCC
[42]. Hence, it is plausible that there is a cause-and-effect
relationship between dysregulated prosurvival PI-3K/AKT
signaling and loss of TRAIL expression in OPM and
OSCC.
Interestingly, oral carcinogens such as tobacco smoke fre-
quently inactivate the tumor suppressor gene p53, thus
depriving its protective role against oral carcinogen-
induced DNA damage [43]. TRAIL-induced apoptosis of
transformed/dysplastic cells is independent of p53 status
[34,44], hence, TRAIL may act as a substitute guardian
against malignant transformation by eliminating trans-
formed cells during the initial genesis OPM. Thus, TRAIL
down-regulation may allow clonal expansion of trans-
formed cells by protecting them from apoptosis, thereby
increasing the risk of malignant progression.
TRAIL protein detection was mostly negative or only
focally positive in isolated tumor cells in both primary
and metastatic OSCC tumors, and our Western blot anal-
ysis clearly demonstrated the lack of TRAIL protein in pri-
mary and metastatic OSCC cell lines. Our microarray data
also confirmed low levels of TRAIL mRNA in primary and
metastatic OSCC cell lines compared to NOM. Our find-
ings are not, however, in agreement with a previous study
reporting the expression of TRAIL protein in primary
OSCC tumor specimens and TRAIL mRNA expression in
established OSCC cell lines [24,25]. That study used RT-
PCR, which can presumably detect much lower levels of
TRAIL mRNA compared to our microarray analysis. More-
over, that study did not compare the TRAIL mRNA levels
of OSCC cell lines with NOM to determine significant dif-
ferences in their respective expression levels. The micro-
array chip used in our study included three different probe
sets for TRAIL which further increased the specificity and
reliability of the data. Nevertheless, tumor heterogeneity
Expression patterns of TRAIL-R, DR4, DR5, DcR1 and DcR2 are not different between primary and synchronous metastatic OSCCFigure 11
Expression patterns of TRAIL-R, DR4, DR5, DcR1 and DcR2 are not different between primary and synchronous metastatic 
OSCC. Immunohistochemical expression patterns of TRAIL receptors in primary (Iry) and lymph node metastasis (Met.) of 
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Table 3: Correlation between TRAIL/TRAIL-R expression patterns and apoptosis rates of tumor cells and tumor-infiltrating 
lymphocytes within primary oral squamous cell carcinomas
TRAIL/TRAIL-R LICASP-TU Mean ± SEM LICASP-LY Mean ± SEM
TRAIL
Focally positive tumors (n = 31; 73%) 3.43 ± 0.5 5.95 ± 0.74
Negative tumors (n = 11; 27%) 3.20 ± 0.83 10.91 ± 2.9
P value 0.818 0.145
DR4
High expressors (IHC score > 2; n = 28; 67%) 2.89 ± 0.47 5.80 ± 0.8
Low expressors (IHC score < 2; n = 14; 33%) 4.4 ± 0. 93 9.24 ± 2.2
P value 0.11 0.07
DR5
High expressors (IHC score > 2; n = 9; 21%) 2.4 ± 0.57 7.4 ± 3.01
Low expressors (IHC score < 2; n = 33; 79%) 3.61 ± 0.51 6.73 ± 0.81
P value 0.24 0.75
DcR1
High expressors (IHC score > 2; n = 36; 86%) 3.55 ± 0.48 6.56 ± 0.77
Low expressors (IHC score < 2; n = 6; 14%) 3.53 ± 1.32 8.2 ± 3.4
P value 0.99 0.48
DcR2
High expressors (IHC score > 2; n = 1; 2%) 12.2 20.2
Low expressors (IHC score < 2; n = 41; 98%) 3.15 ± 0.37 6.5± 0.78
P value N/A N/A
Histology
Conventional squamous cell carcinoma (n = 33) 2.67 ± 0.62 2.67 ± 0.62
Basaloid squamous cell carcinoma (n = 9) 3.62 ± 0.51 11.27 ± 2.21
P value 0.36 0.013
Table 2: Correlation between TRAIL receptor expression levels and clinicopathologic prognosticators in primary OSCC
Variables DR4 Mean ± SD DR5 Mean ± SD DcR1 Mean ± SD DcR2 Mean ± SD
Histologic grade
Well differentiated (n = 6) 2.96 ± 0.53 1.23 ± 0.71 2.40 ± 1.05 0.55 ± 0.38
Mod. differentiated (n = 19) 2.03 ± 0. 91 1.51 ± 0.79 2.46 ± 0.65 0.69 ± 0.42
Poorly differentiated (n = 8) 2.15 ± 0.86 1.01 ± 0.26 2.61 ± 0.61 0.80 ± 0.73
Basaloid SCC (n = 9) 2.18 ± 1.05 1.43 ± 0.70 2.64 ± 0.54 0.39 ± 0.36
P value 0.189 0.366 0.864 0.305
Tumor size
pT1 (n= 14) 2.45 ± 1.06 1.19 ± 0.65 2.41± 0.57 0.53 ± 0.47
pT2 (n = 23) 2.16 ± 0.85 1.44 ± 0.63 2.60 ± 0.77 0.60 ± 0.41
pT3 (n = 2) 2.05 ± 0.21 2.5 ± 0.98 2.45 ± 0.07 0.75 ± 0.07
pT4 (n = 3) 1.93 ± 1.15 2.7 ± 0.57 2.7 ± 0.7 1.10 ± 1.04
P value 0.734 0.03 0.846 0.336
Lymph node status
pN0 (n = 25) 2.27 ± 0.88 1.36 ± 0.79 2.67 ± 0.75 0.69 ± 0.55
pN1/2 (n = 17) 2.21 ± 0.99 1.35 ± 0.57 2.34 ± 0.50 0.53 ± 0.36
P value 0.842 0.986 0.098 0.256
BMC Cancer 2007, 7:108 http://www.biomedcentral.com/1471-2407/7/108and the differences in the specificity of the TRAIL antibody
used in the two investigations may account for the dis-
crepancies in the OSCC TRAIL expression data.
Expression of DR4, DR5 and DcR1 receptors are not 
significantly altered during oral cancer progression
Relative expression levels of TRAIL death and decoy recep-
tors are critical for exploiting therapeutic possibilities
based on TRAIL/TRAIL-R interaction in OPM and OSCC
[7,10,33,45]. Expression of these three receptors by OSCC
seems to depend at least in part on whether or not they are
expressed by the parental oral epithelium from which the
tumors arose. Moreover, expression of all three receptors
in the tumor cells were higher than in adjacent NOM, a
feature also reported for melanomas and breast and colon
carcinomas [46-48]. In contrast, DcR2 expression was sig-
nificantly lower in OSCC compared to the adjacent NOM.
Loss of DcR2 expression in malignant tumor cells has
been attributed to aberrant promotor methylation [49].
DcR1, DR4 and DR5 are very frequently overexpressed in
dysplastic oral mucosa, as well as primary and metastatic
OSCC tumor specimens. All primary OSCC specimens
examined by us expressed either DR4 or DR5 or both at
high levels. Among the death-inducing receptors, DR4
was expressed more frequently in OSCC than DR5, as also
observed by others in head and neck squamous cell carci-
nomas  [25]. Therefore, it would seem that the DR4-tar-
geted humanized agonist antibody (HGS-ETR1) would be
a better choice than the DR5-targeted antibody (HGS-
ETR2) for OSCC clinical trials.
TRAIL death-inducing receptors DR4 and DR5 are consid-
ered tumor suppressors because their loss is expected to
provide a survival advantage to the tumor cells. Con-
versely, overexpression of the anti-apoptotic decoy recep-
tors DcR1 and DcR2 is expected to promote malignant
progression. Therefore, we evaluated the association
between the expression levels of these receptors and cer-
tain accepted prognostic indicators such as tumor size,
nodal status and histologic tumor grade. Expression levels
of these receptors failed to show any significant correla-
tion with either nodal status or tumor grade, and there
was no significant association between DR4, DcR1 and
DcR2 expression levels and tumor size. However, DR5
expression correlated positively with tumor size. Such an
association is in conflict with its proposed pro-apoptotic
and tumor-suppressive function yet a similar observation
is also made in breast cancers, in which high DR5 expres-
sion has correlated with nodal status, tumor size, and
poor survival rate [48]. Similarly, high DR5 but not DR4
expression correlated with decreased survival in patients
with non-small-cell lung cancers [50]. DR5 expression is
induced by DNA damage and the induction is both wild-
type p53 dependent and independent [51]. Activation of
endogenous NF-kB factors by TNF-α also induces DR5
expression in tumor cells [52]. Thus, anti-apoptotic NF-kB
activation may explain the association between increased
DR5 expression and larger tumor size.
TRAIL and TRAIL-R expression in OSCC does not influence 
tumor cell and tumor infiltrating lymphocyte apoptosis 
rates
Susceptibility of OSCC cells to TRAIL-mediated apoptosis
is dependent on their relative expression levels of death-
inducing receptors DR4 and DR5 versus decoy receptors
DcR1 and DcR2. OSCC expressing high levels of DR4 and/
or DR5 will be more susceptible to apoptosis than tumors
expressing low levels of these receptors. Conversely,
OSCC expressing high levels of decoy receptors often
shows reduced tumor cell apoptosis rates. However, our
data did not show any significant difference in the tumor
cell apoptosis rates for primary OSCC with high and low
levels of DR4 and/or DR5 expression, or for differential
expression levels of decoy receptors DcR1 and DcR2.
TIL represent one of the manifestations of host immune
response against malignancy [53], and several clinical
studies have documented the prognostic significance of
Immunohistochemical staining for cleaved caspase 3 to detect apoptotic cells among tumor cells and tumor-infiltrat-ing lymp cytesFi ure 12
Immunohistochemical staining for cleaved caspase 3 to 
detect apoptotic cells among tumor cells and tumor-infiltrat-
ing lymphocytes. Examples showing the detection apoptotic 
cells among tumor cells (LI-Cas-Tu)) and TIL (LI-Cas-TIL) 
based on their immunoreactivity for cleaved caspase-3 (× 
400).Page 10 of 13
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Apoptosis of TIL in OSCC leads to the depletion of lym-
phocytes and negatively affects their prognosis [54]. This
is further supported by our finding that TIL apoptosis rates
in basaloid squamous cell carcinomas, a very aggressive
variant of OSCC [56,57], were 5-fold higher than in con-
ventional OSCC. However, TRAIL/TRAIL-R expression
patterns or tumor cell apoptosis rates were not signifi-
cantly different between basaloid squamous cell carci-
noma and conventional OSCC. Depletion of TIL in
malignant tumors is mediated by a counterattack against
Fas-bearing lymphocytes by FasL-expressing tumor cells
[58]. Therefore, the potential of tumor-cell-derived TRAIL
cytotoxicity against TIL has been proposed by some stud-
ies [59]. However, our study did not find any significant
difference in the TIL apoptosis rate between focal TRAIL-
positive and TRAIL-negative OSCC.
Conclusion
Our investigation has shown that TRAIL is constitutively
expressed in normal oral mucosa but its expression is
gradually lost in oral premalignant and malignant epithe-
lia. OSCC more frequently expresses DcR1, followed by
DR4 and DR5. Moreover, expression of DR4, DR5 and
DcR1 are up-regulated in premalignant and malignant
oral epithelia compared to normal oral epithelium. A par-
tial loss of DcR2 expression is also noted in premalignant
and malignant oral epithelia compared to normal oral
epithelia, and DR5 expression is significantly associated
with larger tumor size. Expression levels of TRAIL recep-
tors show no significant correlation with nodal status and
apoptosis rates of tumor cells and TIL.
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